A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma

Collaborators, Affiliations

Pdac Chemo Sensitivity Prediction Working Group:
Martin Bigonnet⁴, Claire Bongrain⁵, Emilie Lermite⁶, Patrick Pessaux⁷, Fabio Giannone⁷, Marie-Pierre Chenard⁷, Sophie Michalak⁸, Rémy Nicolle⁸, Marion Rubis⁵, Flora Poizat⁵, Marc Giovannini⁵, Fabrice Caillol⁵, Philippe Rochigneux⁵

¹ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
² Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France; Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.
³ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France; Endocrine and Visceral Surgery Department, University Hospital Angers, Angers, France; Haut Anjou Hospital Center, Château-Gontier, France.
⁴ PredictingMed, Luminy Science and Technology Park, Marseille, France.
⁵ Institut Paoli-Calmettes, Medical Oncology Department, Marseille, France.
⁶ Endocrine and Visceral Surgery Department, University Hospital Angers, Angers, France.
⁷ Department of General, Digestive, and Endocrine Surgery, Nouvel Hôpital Civil, Strasbourg, France.
⁸ Department of Pathology, University Hospital Angers, Angers, France.
⁹ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France; Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France. Electronic address: juan.iovanna@inserm.fr.
¹⁰ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France. Electronic address: nelson.dusetti@inserm.fr.

Nicolas Fraunhoffer et al. Gastroenterology. 2023 Mar.

. 2023 Mar;164(3):476-480.e4.

doi: 10.1053/j.gastro.2022.11.035. Epub 2022 Dec 7.

Pdac Chemo Sensitivity Prediction Working Group:
Martin Bigonnet⁴, Claire Bongrain⁵, Emilie Lermite⁶, Patrick Pessaux⁷, Fabio Giannone⁷, Marie-Pierre Chenard⁷, Sophie Michalak⁸, Rémy Nicolle⁸, Marion Rubis⁵, Flora Poizat⁵, Marc Giovannini⁵, Fabrice Caillol⁵, Philippe Rochigneux⁵

¹ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
² Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France; Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.
³ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France; Endocrine and Visceral Surgery Department, University Hospital Angers, Angers, France; Haut Anjou Hospital Center, Château-Gontier, France.
⁴ PredictingMed, Luminy Science and Technology Park, Marseille, France.
⁵ Institut Paoli-Calmettes, Medical Oncology Department, Marseille, France.
⁶ Endocrine and Visceral Surgery Department, University Hospital Angers, Angers, France.
⁷ Department of General, Digestive, and Endocrine Surgery, Nouvel Hôpital Civil, Strasbourg, France.
⁸ Department of Pathology, University Hospital Angers, Angers, France.
⁹ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France; Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France. Electronic address: juan.iovanna@inserm.fr.
¹⁰ Cancer Research Center of Marseille (CRCM), INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France. Electronic address: nelson.dusetti@inserm.fr.

No abstract available

Publication types